This is the case of a 39-year-old woman, with no family history of breast cancer, with a painless palpable lump recently appeared on CSI left breast, without blushing or heat. The patient came to our Unit to start imaging studies. Mammographic, ultrasonographic, and MR breast findings, and anato-pathological analysis are described below. In the mammography, we can see a left global asymmetry that primarily affects the upper quadrants (Figure 1), associating faint and few fine and heterogeneous scattered microcalcifications. Sonographically, a mass measuring 47mm, consisting of numerous small and simple cysts grouped, with some ectatic canalicular segments and moderate hyperemia regional (Figure 2) with a hard and stiff behavior in the US-elastography, so additional histological study is made. 14G biopsy is performed using ultrasound with the pathologic result of “fibrocystic changes”. Given these findings, it was decided to perform an image control in 3 months, in this case with breast MRI, to assess behavior and evolution of the lesion, in which we found an asymmetric regional enhancement in the upper left quadrants, with heterogeneous internal enhancement with wash-out curves (Figure 3) and decrease of ADC value. Therefore, we classify it as BI-RADS 5 recommending second look ultrasound and new biopsy. In this case, we use 11G needle, extracting 6 cylinders with histopathological result of “complex fibrocystic breast disease with intraductal microcalcifications”. In posterior clinical session, it determined to make a lumpectomy to remove the lesion for a complete histological study.
Histological result of the piece finally threw a “extensive papillomatosis with intraductal apocrine changes and focal epithelial hyperplasia with atypia and complex fibrocystic breast disease with sclerosing adenosis”. P-63 immunostaining performed, and CK-Actin m.1iso 34B12 myoepithelial cells clearly observing and confirming the diagnosis of fibrocystic breast disease complex.

This case highlights the complexity of a benign entity, known to all, debutting as a false positive MRI at the expense of severe proliferative change. This is a benign process with radiological border-line and suspicious presentations, that shares morphology and kinetics features of malignancy on MR. Therefore we need to make a small literature review of a so simple entity and so complex as the same time, as the mammary dysplasia, mainly from the point of view of MRI, given the short literature exists about it.

Among all benign disease that affects the breast at some period of life of women, fibrocystic breast disease is the most anxiety and anguish generated, being one of the most frequent reasons for consultation, estimating that between 45 and 85 % of patients consult for this reason.

The nomenclature to refer to this entity is comprehensive: fibrocystic breast disease, fibrocystic changes, mammary dysplasia, scleral-cystic breast disease, fibrocystic breast changes or adenosis, mainly. Macroscopically it characterized by a marked proliferation of connective tissue and cysts of varying size, whose content is serous-yellowish; microscopically they show epithelial lining these cysts that may have some degree of hyperplasia, sometimes adding an accessory layer of myoepithelial cells. Fibrocystic changes is the most common benign breast entity, in fact around 50% of women have these changes after autopsies that can be qualified of this nature.

These changes are the result of the distortion produced periodically by menstrual changes on the ductal epithelium, and also secondary to changes in hormone levels of estrogen and progesterone, with the first increase and the second decrease in breast stroma. It is therefore a chronic and bilateral clinicopathological process consisting essentially of a proliferation of the epithelium lining the ducts, secondarily leading to a reaction fibrotic local connective component, which leads to the formation of cysts localized or diffuse way. It is a hyperplastic and proliferative process we observe, in particular, between 25 and 45 years old.

Figure 3 There is an important asymmetric regional enhancement in the upper left quadrants in contrast-enhanced T1-weighted fat-saturated

A. With internal heterogenous enhancement.
B. Color-coded map shows foci with the maximum slope of enhancement increase (red) after contrast material injection.
C. Wash-out curve or type III.

Fibrocystic tissue is often difficult to distinguish from normal breast parenchyma, acquiring a variable appearance depending on the water content and collagen of different tissues. In fact, the MR presentation can be very similar to mammographic, with small well defined and grouped cysts, or we can see after administration of contrast a dotted striking patchy pattern and diffuse, even as in our case, a regional enhancement or even a heterogeneous mass. Proliferative changes may also be arranged as a mass effect by the compressive effect on the stroma, altering the configuration and arrangement of the glandular component, which is indistinguishable from DCIS or invasive carcinoma.

FCC is a benign and very common entity in our daily practice, with majority premenopausal presentation. Clinically it is seen in approximately 50% of women seeking consultation and about 90% of histological studies.

This condition can cause pain in a particular area of the breast, in all of it or both, usually cyclically coinciding particularly with premenstrual changes (mastodinia). In the physic examination we can detect hardened areas or nodular areas that are located more frequently in CCSSEE. This behavior can easily simulate or hinder cancer diagnosis, so is always necessary imaging studies to exclude neoplasms.

Mammography and ultrasound form the mainstay in diagnostic imaging in breast disease, because normally the breasts are dense and the mammographic sensitivity is limited. The complete parenchymal ultrasound study confirms the nature of nodular formations and characterizes those areas detected at palpable exploration. However, in a not inconsiderable percentage of cases of greater complexity it is necessary to complete the assessment with breast MRI to evaluate their behavior and exclude malignancy. This tool has gradually tightened his grip on diagnostic imaging of breast disease, and although it has taken years to standardize their indications, this is a sensitive and specific for the diagnosis of benign pathology technique.

Citation: Fernadez E. Something as simple and as complex as fibrocystic mastopathy review of MRI findings in a case report. Int J Radial Radiat Ther. 2017;2(1):16–19. DOI: 10.15406/ijrrt.2017.02.00014
**MRI features**

The dynamic study in FCC will show regularly punctuate enhancements, bilateral distribution and generally patchy and diffuse, moderately symmetrical distribution. The numerous punctuate images we see usually have demonstrated respond to a focal adenosis.\(^{12}\)

It is difficult to differentiate with this technique normal of fibrocystic tissue glandular parenchyma on T1 and T2 weighted sequences without contrast. The heterogeneity observed after administration of contrast is due in many cases to areas of epithelial proliferation alternating with areas of regressive changes, as fibrosis and cysts. True cystic disease occurs more frequently in the early 40s, due to ductal epithelium hyperplasia and dilation of the ducts in the menstrual phase, not compensated by the involution of the parenchyma.

The FCC with epithelial proliferation has been associated with an increased risk of cancer, especially if it is accompanied by cellular Atypia.\(^{13,15}\) In fact, the main problem of patients affected by FCC is correctly diagnosed epithelial hyperplasia and malignant disease associated in many cases. Although these patients may express a clinical and image findings fairly typical, for some of them it is not enough only imaging study with mammography and ultrasound. Both malignant and benign breast conditions can share morphologic and kinetic patterns. Since MRI is increasingly used to screen young high risk women, diagnostic ambiguity will become more common due to the high incidence of fibrocystic breast seen in this age group. Benign breast disease includes proliferative changes, intraductal papillomas, granular cell tumors, fibroadenomas, mastitis, fat necrosis, pseudoangiomatous stromal hiperplasia, epidermal inclusion cyst, and benign intrammary lymph nodes.\(^{13,15}\)

It’s very important understand MR imaging features of FCC to exclude malignancy, avoid unnecessary biopsy, and of course, reduce patient anxiety.\(^{15}\) There are very few MRI studies about fibrocystic breast, and I consider relevant learn more about the behavior of this disease in MR given the ability to simulate and mask the cancer.

As we know the behavior of cancer in MRI it is studied from morphological and kinetic criteria, expressed by usual irregular or symmetrical distribution, rapidly initial uptake of contrast with subsequent washing. On the other hand, we also know that in many cases benign pathology may present criteria of malignancy in MRI, resulting in numerous biopsies and also in false positives. FCC has an indistinct vessel supply to the duct and can cause little inflammation around the duct. This can difficult the evaluation in MRI. But the other one displayed atypical epithelial hyperplasia accompanied with FCC.\(^{13,18}\) Kiyak et al.\(^{13}\) found that the analysis of enhancement kinetics may be more useful to identify premalignant lesions as atypical epithelial hyperplasia and cancer from other breast lesions provided that corrections are made for the true phase of menstrual cycle.

The enhancement is due to a number of biologic factors, including an increase in vessel number and size, increased vascular permeability, and increased cellularity.\(^{17,18}\) Maurice et al.\(^{19-21}\) reported that morphological criteria have less false positive diagnoses of malignant lesions than of kinetic criteria.\(^{19-21}\) This finding was comparable to the study of Goto et al.,\(^{22}\) which concluded that the sensitivity and specificity of the morphologic pattern were significantly higher than those of the enhancement features based on a study of 144 malignant and 60 benign breast lesions.\(^{22}\)

Other studies have shown that most (60–80%) enhancing lesions recommended for biopsy are ultimately determined to be benign.\(^{23,24}\) Cystic apocrine metaplasia is a subset of fibrocystic changes featuring discrete clustered cysts that are lined by apocrine epithelium. Alexander et al.\(^{18}\) found that most (67%) MRI-guided breast biopsies are performed on benign lesions, with many containing varying elements of fibrocystic change.\(^{18}\) Also, recent studies have described an increased detection of apocrine lesions with MRI.

In the short literature reviewed the most relevant features in MRI in the FCC is non-mass regional enhancement and predominantly curves type II. Nodular enhancements in general tend to have smooth edges and size no larger than 2cm. Yabauchi H et al.\(^{23}\) found that lesions larger than 10mm tended to be malignant, and lesions equal or smaller than 5 mm tended to be benign. Lesions with early enhancement peak tended to be malignant, whereas those with persistent enhancement tended to be benign.\(^{23}\)

Also, Liberman L et al.\(^{26}\) studied the importance of lesion size on the positive predictive value (PPV) of biopsy in MRI detected breast lesions. It was found that the frequency of malignancy increased significantly with lesion size. Those lesions less than 5mm had a 3% chance of being malignant, lesions with size 5–9mm a 17% and lesions 10–14mm a 25% malignancy rate. So they concluded that biopsy is rarely for lesions smaller than 5mm because of their low (3%) likelihood of cancer.\(^{26}\)

Florea et al.\(^{27}\) establish that hypovascular lesions, non-rigid focal mastopathic changes are usually associated with non proliferative lesions. Stiff or hypervascular lesions better correlate with proliferative changes, and for those cases with imaging risk features, such as wash-out, differential diagnosis with in situ or invasive neoplasia is impossible on imaging criteria alone.\(^{27}\)

Breast MRI compared to mammography and sonography, had worse diagnostic performance (82%, 55% and 70% false positive rate, respectively). This fact actually supports the unreliability of using the pattern of enhancement kinetics in diagnosing breast malignancy.\(^{15}\)

**Conclusion**

This entity is a real challenge for the breast radiologist. Why? , because more than 50% of lesions we see in the context of FCC show morphological and kinetic criteria of malignancy, so in the present moment we cannot avoid biopsies, much less when it comes to a patient with breast cancer. It’s also necessary to know more about this disease to properly select patients which need more aggressive treatments.

I consider further studies are needed about the behavior of a simple and complex as the FCC in the field of breast MRI pathology.

**Acknowledgements**

None.

**Conflict of interest**

Author declares that there is no conflict of interest.

**References**

1. Gallo JL, Mas MP, Vico I, et al. Mastopatia fibroquística. Aspectos controvertidos Fibrocystic breast disease. Controversial aspects. Clínica e Investigación en Ginecología y Obstetricia. 2013;40(6):269–276.
2. Martin Etchart. Lecciones de Anatomia Patológica. Procesos no tumo-
rales de mama. Chile.
3. Love S, Gelman RS, Silen W. Fibrocystic “disease” of the breast, a non de-

ces? The New England Journal of Medicine. 1982;307(16):1010–1014.
4. Kopans D. Breast Imaging. 2nd ed. 1999. 18p.
5. Morris EA. Review of Brest MRI: indications and limitations. Semin

Roentgenol. 2001;36(3):226–237.
6. Nanes LW, Schnall MD, Orel SG, et al. Correlation of lesion appearance

and histologic findings for the nodes of a breast MR imaging interpreta-
tion model. Radiographics. 1999;19(1):79–92.
7. Gugray M, Sahin A. Benign breast desesases: Classification, diagnosis and

management. Obstet Gynecol. 2006;11(5):435–449.
8. Fitzgibbons PL, Henson DE, Hutter RV. Benign breast changes and the

risk for subsequent breast cancer: an update of the 1985 consensus state-
mnt. Cancer Committee of the College of American Pathologists. Arch

Pathol Lab Med. 1998;122(12):1053–1055.
9. Sarrelly R, Squartini F. Fibrocystic condition and “at risk” lesions in

asymptomatic breasts: a morphologic study of postmenopausal women.
Clin Exp Obstet Gynecol. 1991;18(4):271–279.
10. Wu C, Ray RM, Lin MG, et al. A case–control study of risk factors for

fibrocystic breast conditions. Am J Epidemiol. 2004;160(10):945–960.
11. Santen RJ, Mansel R. Benign breast disorders. The New England Journal

of Medicine. 2005;353(3):275–285.
12. Morris E, Liberman L. Breast MRI: diagnosis and intervention. Radiol-

ogy. 2010;243(1):117.
13. Kiyak G, Asik E, Yazgan A. Importance of magnetic resonance imaging in

patients with fibrocystic changes. Bratisl Lek Listy. 2011;112(9):506–509.
14. Scott EB. Fibrocystic breast disease. Am Fam Physician. 1987;36:119–126.
15. Chen JH, Nalcioğlu O, Su MY. Fibrocystic change of the breast present-
ing as a focal lesion mimicking breast cancer in MR imaging. J Magn

Reson Imaging. 2008;28(6):1499–1505.
16. Zhu JZ, Kurihara Y, Kanemaki Y, et al. Diagnostic accuracy of high-

resolution MRI using a microscopy coil for patients with presumed

DCIS following mammography screening. J Magn Reson Imaging.

2007;25(1):96–103.
17. Teilke A, Behr O, Schmidt M, et al. Dynamic MR imaging of breast

lesions: correlation with microvessel distribution pattern and histologic

characteristics of prognosis. Radiology. 2006;239(2):351–360.
18. Alexander DR, Marotti J, Bond J, et al. Breast MRI–Detected Cystic

Apocrine Metaplasia: Imaging Features With Microvessel Analysis and

Histologic Correlation. AJR Am J Roentgenol. 2015;204(1):211–218.
19. Van den Bosch MA, Daniel BL, Mariano MN, et al. Magnetic resonance

imaging characteristics fibrocystic change of the breast. Invest Radiol.

2005;40(7):436–441.
20. Chen JH, Liu H, Baek HM, et al. MR Imaging Features of Fibrocystic

Change of the Breast. Magn Reson Imaging. 2008;26(9):1207–1214.
21. Binokay F, Soyupak S, Bicakci K, et al. Wide spectrum of fibrocystic

changes: MR findings. ECR. 2010.
22. Goto M, Ito H, Akazawa K, et al. Diagnosis of breast tumors by contrast–

enhanced MR imaging: comparison between the diagnostic performance

dynamic enhancement patterns and morphologic features. J Magn Res-

on Imaging. 2007;25(1):104–112.
23. Siziopikou KP, Jokich P, Cobleigh M. Pathologic findings in MRI–gui-
ded needle core biopsies of the breast in patients with newly diagnosed

breast cancer. Int J Breast Cancer. 2011;2011:613285.
24. Schell AM, Rosenkranz K, Lewis PJ. Role of breast MRI in the preope-

rative evaluation of patients with newly diagnosed breast cancer. AJR Am

J Roentgenol. 2009;192(5):1438–1444.
25. Yabuuchi H, Kuroiwa T, Kusumoto C, et al. Incidentally detected lesions

on contrast–enhanced MR imaging in candidates for breast–conserving

therapy: correlation between MR findings and histological diagnosis. J

Magn Reson Imaging. 2006;23(4):486–492.
26. Liberman L, Mason G, Morris EA, et al. Does size matter? Positive pre-
dictive value of MRI–detected breast lesions as a function of lesion size.
AJR Am J Roentgenol. 2006;186(2):426–430.
27. Florea M, Chiorean AR, Roman RA, et al. Imaging spectrum of breast focal

fibrocystic changes: mammography, conventional ultrasound, elas-
tography and MRI appearances; pathology correlations and differential
diagnosis. ECR. 2014.

Citation: Fernadez E. Something as simple and as complex as fibrocystic mastopathsy review of MRI findings in a case report. Int J Radial Radiat Ther.
2017;2(1):16–19. DOI: 10.15406/ijrrt.2017.02.00014